© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 85247 refers to a laboratory test that performs a multimetric analysis of factor VIII and von Willebrand factor (VWF). This test is crucial in understanding the coagulation process, as factor VIII, also known as the antihemophilic factor, and VWF work together to form a unique plasma glycoprotein essential for normal blood clotting. VWF serves as the carrier protein for factor VIII, stabilizing its procoagulant activity, which is vital for effective hemostasis. In the bloodstream, VWF exists in two forms: one that circulates freely and another that is bound to the alpha granules of circulating platelets. The synthesis and release of plasma VWF occur in vascular endothelial cells, while platelet VWF is produced by megakaryocytes in the bone marrow. The multimetric analysis test encompasses several components, including the activity of factor VIII, the activity of VWF, and the VWF ristocetin cofactor activity. This comprehensive analysis is particularly ordered when there is a strong suspicion of inherited von Willebrand disease, a genetic disorder that affects blood clotting. To perform this test, a blood sample is collected through a venipuncture, which is separately reportable. The analysis is conducted on platelet-poor plasma using various methodologies such as electrophoresis, western blot, clotting assays, microlatex particle-mediated immunoassays, or platelet agglutination techniques.
© Copyright 2025 Coding Ahead. All rights reserved.
The multimetric analysis of factor VIII and von Willebrand factor is indicated in specific clinical scenarios where there is a suspicion of bleeding disorders. The primary indication for ordering this test is when inherited von Willebrand disease is highly suspected. This condition is characterized by a deficiency or dysfunction of von Willebrand factor, leading to increased bleeding tendencies. The test may also be indicated in patients presenting with unexplained bleeding, easy bruising, or a family history of bleeding disorders, as it helps in diagnosing and differentiating von Willebrand disease from other coagulation disorders.
The procedure for conducting the multimetric analysis of factor VIII and von Willebrand factor involves several key steps to ensure accurate results. First, a blood sample is obtained from the patient through a venipuncture, which is a standard method for collecting blood. This sample must be handled carefully to prevent contamination and ensure the integrity of the results. Once the blood is collected, it is processed to obtain platelet-poor plasma, which is essential for the analysis. This is typically achieved by centrifuging the blood sample to separate the plasma from the cellular components. The platelet-poor plasma is then subjected to various testing methodologies, including electrophoresis, western blot, clotting assays, microlatex particle-mediated immunoassays, or platelet agglutination techniques. Each of these methods is designed to measure the activity levels of factor VIII and von Willebrand factor, as well as the ristocetin cofactor activity, providing a comprehensive assessment of the patient's coagulation status.
After the multimetric analysis is completed, the results are interpreted by healthcare professionals to assess the patient's coagulation status. Depending on the findings, further diagnostic testing or treatment may be recommended. It is important for the healthcare provider to discuss the results with the patient, especially if any abnormalities are detected that may indicate a bleeding disorder. Patients may be advised on any necessary follow-up appointments or additional tests that may be required to confirm a diagnosis or to monitor their condition. Additionally, the healthcare provider may provide guidance on managing any bleeding risks associated with the findings of the test.
| Short Descr | CLOT FACTOR VIII MULTIMETRIC | Medium Descr | CLOTTING FACTOR VIII MULTIMETRIC ANALYSIS | Long Descr | Clotting; factor VIII, von Willebrand factor, multimetric analysis | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 2 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Changed | Short Descriptor changed. |
| 2001-01-01 | Changed | Code description changed. |
| 1993-01-01 | Added | First appearance in code book in 1993. |
Get instant expert-level medical coding assistance.